Clear Street’s BridgeBio Oncology BBOT Stock Holding History

Clear Street’s Portfolio BBOT Stock Details BBOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-205,666	Closed	-$2.18M	–	892
2025 Q2	$2.18M	Buy	+205,666	New	+$2.22M	0.01%	89

Other funds holding BBOT

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Clear Street's BBOT Position: Q3 2025 in Review

Clear Street sold out of BridgeBio Oncology (BBOT) in Q3 2025, closing a stake of 205,666 shares — an estimated $2.18M sold.

Clear Street first reported a position in BBOT in Q2 2025 and held it in 1 quarter. The position peaked at $2.18M in Q2 2025. 42 funds tracked by Wall St. Rank hold BBOT as of Q3 2025.

Clear Street reported no remaining BridgeBio Oncology position as of Q3 2025 after selling out during the quarter.
Clear Street sold 205,666 BridgeBio Oncology shares in Q3 2025, an estimated $2.18M.
Clear Street first reported a position in BridgeBio Oncology in Q2 2025 and held it in 1 quarter.
Clear Street's BridgeBio Oncology position peaked at $2.18M in Q2 2025.
42 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q3 2025.

Based on Clear Street's 13F filing for Q3 2025, filed 14 Nov 2025.